Pharmadrug Inc.: Pharmadrug Announces Successful Completion of Pre-IND Meeting with FDA Regarding Proposed Development of Its Cepharanthine for Treatment of Mild to Moderate COVID-19 Infection

Established alignment with FDA on the path forward for the development of PD-001, a patented enteric-coated formulation of cepharanthine, towards clinical studies for mild-moderate COVID-19 infectionMeeting

Related Keywords

Saijo ,Tokushima ,Japan ,Germany ,United States ,Akanaya ,Wakayama ,South Africa ,Toronto ,Ontario ,Canada ,Dejima ,Japan General ,Zimmerberg ,Baden Wüberg ,Canadian ,South African ,German ,Daniel Cohen ,Van Slyke ,Baillyc Cepharanthine ,Newsfile Corp ,Schedulei European Union ,Pharmadrug Inc ,European Union ,Drug Administration ,Breakthrough Designation ,Manufacturing Control ,Chief Scientific Officer ,Middle East ,Cepharanthine May Work ,Block Coronavirus ,Enteric Coated Cepharanthine ,Pharmadrug Production Gmbh ,Sairiyo Therapeutics ,Super Smart ,Regarding Forward Looking Information ,Drug Repurposing Screens ,Pharmadrug ,Nnounces ,Uccessful ,Completion ,Meeting ,Egarding ,Roposed ,Development ,Cepharanthine ,Treatment ,Ild ,Moderate ,Covid ,Infection ,